{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:39:26Z","timestamp":1790710766703,"version":"4.1.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) shows constitutive activation of canonical and noncanonical nuclear factor \u03baB (NF-\u03baB) signaling via genetic mutations or tumor microenvironment (TME) stimulations. A subset of MM cell lines showed dependency for cell growth and survival on the canonical NF-\u03baB transcription factor RELA alone, suggesting a critical role for a RELA-mediated biological program in MM pathogenesis. Here, we determined the RELA-dependent transcriptional program in MM cell lines and found the expression of the cell surface molecules interleukin-27 receptor-\u03b1 (IL-27R\u03b1) and the adhesion molecule JAM2 to be responsive to RELA at the messenger RNA and protein levels. IL-27R\u03b1 and JAM2 were expressed on primary MM cells at higher levels than on healthy long-lived plasma cells (PCs) in the bone marrow. IL-27 activated STAT1, and to a lesser extent STAT3, in MM cell lines and in PCs generated from memory B cells in an IL-21\u2013dependent in\u00a0vitro PC differentiation assay. Concomitant activity of IL-21 and IL-27 enhanced differentiation into PCs and increased the cell-surface expression of the known STAT target gene CD38. In accordance, a subset of MM cell lines and primary MM cells cultured with IL-27 upregulated CD38 cell-surface expression, a finding with potential implications for enhancing the efficacy of CD38-directed monoclonal antibody therapies by increasing CD38 expression on tumor cells. The elevated expression of IL-27R\u03b1 and JAM2 on MM cells compared with that on healthy PCs may be exploited for the development of targeted therapeutic strategies that modulate the interaction of MM cells with the TME.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009044","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T18:07:57Z","timestamp":1677866877000},"page":"3874-3890","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Cytokine receptor <i>IL27RA<\/i> is an NF-\u03baB\u2013responsive gene involved in\u00a0CD38 upregulation in multiple myeloma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-1044","authenticated-orcid":false,"given":"Rebecca J.","family":"Brownlie","sequence":"first","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kennedy","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-728X","authenticated-orcid":false,"given":"Erica B.","family":"Wilson","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Milanovic","sequence":"additional","affiliation":[{"name":"2Institute for Cancer Genetics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire F.","family":"Taylor","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-4574","authenticated-orcid":false,"given":"Dapeng","family":"Wang","sequence":"additional","affiliation":[{"name":"3Leeds Omics, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Davies","sequence":"additional","affiliation":[{"name":"4Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Owston","sequence":"additional","affiliation":[{"name":"5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom"},{"name":"6National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-0555","authenticated-orcid":false,"given":"Emma J.","family":"Adams","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Stephenson","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Caeser","sequence":"additional","affiliation":[{"name":"7Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-3418","authenticated-orcid":false,"given":"Benjamin E.","family":"Gewurz","sequence":"additional","affiliation":[{"name":"8Division of Infectious Diseases, Brigham & Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-7696","authenticated-orcid":false,"given":"Peter V.","family":"Giannoudis","sequence":"additional","affiliation":[{"name":"9Leeds Orthopaedic & Trauma Sciences, Leeds General Infirmary, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Scuoppo","sequence":"additional","affiliation":[{"name":"2Institute for Cancer Genetics, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom"},{"name":"6National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-2033","authenticated-orcid":false,"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[{"name":"7Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-7119","authenticated-orcid":false,"given":"Reuben M.","family":"Tooze","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-6759","authenticated-orcid":false,"given":"Gina M.","family":"Doody","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"10CRUK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-3820","authenticated-orcid":false,"given":"David R.","family":"Westhead","sequence":"additional","affiliation":[{"name":"4Bioinformatics Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4789-967X","authenticated-orcid":false,"given":"Ulf","family":"Klein","sequence":"additional","affiliation":[{"name":"1Division of Haematology & Immunology, Leeds Institute of Medical Research at St. James\u2019s Hospital, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2023080716253521200_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"2023080716253521200_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10272","key":"2023080716253521200_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"2023080716253521200_bib4","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"33","key":"2023080716253521200_bib5","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"2023080716253521200_bib6","doi-asserted-by":"crossref","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","article-title":"Harnessing the immune system against multiple myeloma: challenges and opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"2023080716253521200_bib7","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"25","key":"2023080716253521200_bib8","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2023080716253521200_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/cancers13020216","article-title":"Signaling pathway mediating myeloma cell growth and survival","volume":"13","author":"Hideshima","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2023080716253521200_bib10","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023080716253521200_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/ITT.S240886","article-title":"Immunotherapeutic and targeted approaches in multiple myeloma","volume":"9","author":"Nadeem","year":"2020","journal-title":"Immunotargets Ther"},{"issue":"7","key":"2023080716253521200_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023080716253521200_bib13","first-page":"1195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"2023080716253521200_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"2023080716253521200_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.seminoncol.2022.01.005","article-title":"Pathogenic signaling in multiple myeloma","volume":"49","author":"Bolomsky","year":"2022","journal-title":"Semin Oncol"},{"issue":"18","key":"2023080716253521200_bib16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1101\/gad.1228704","article-title":"Signaling to NF-kappaB","volume":"18","author":"Hayden","year":"2004","journal-title":"Genes Dev"},{"key":"2023080716253521200_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2023080716253521200_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","article-title":"Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation","volume":"102","author":"Tarte","year":"2003","journal-title":"Blood"},{"issue":"32","key":"2023080716253521200_bib19","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1073\/pnas.1602728113","article-title":"Transcription factors of the alternative NF-kappaB pathway are required for germinal center B-cell development","volume":"113","author":"De Silva","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7339","key":"2023080716253521200_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2023080716253521200_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"2023080716253521200_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2023080716253521200_bib23","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"issue":"17","key":"2023080716253521200_bib24","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"2023080716253521200_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vrabel","year":"2019","journal-title":"Blood Rev"},{"issue":"3","key":"2023080716253521200_bib26","doi-asserted-by":"crossref","first-page":"e59127","DOI":"10.1371\/journal.pone.0059127","article-title":"Frequent engagement of RelB activation is critical for cell survival in multiple myeloma","volume":"8","author":"Cormier","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2023080716253521200_bib27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1084\/jem.20132613","article-title":"Germinal center B cell maintenance and differentiation are controlled by distinct NF-kappaB transcription factor subunits","volume":"211","author":"Heise","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2023080716253521200_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.immuni.2019.02.004","article-title":"A\u00a0regulatory circuit controlling the dynamics of NFkappaB cRel transitions B cells from proliferation to plasma cell differentiation","volume":"50","author":"Roy","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"2023080716253521200_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"8","key":"2023080716253521200_bib30","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.celrep.2020.01.108","article-title":"Dissecting the regulatory strategies of NF-kappaB RelA target genes in the inflammatory response reveals differential transactivation logics","volume":"30","author":"Ngo","year":"2020","journal-title":"Cell Rep"},{"issue":"6","key":"2023080716253521200_bib31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.celrep.2019.09.087","article-title":"NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor","volume":"29","author":"Bury","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"2023080716253521200_bib32","doi-asserted-by":"crossref","first-page":"113113","DOI":"10.1016\/j.yexcr.2022.113113","article-title":"Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma","volume":"415","author":"Xie","year":"2022","journal-title":"Exp Cell Res"},{"issue":"7","key":"2023080716253521200_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20150191","article-title":"c-Myb is required for plasma cell migration to bone marrow after immunization or infection","volume":"212","author":"Good-Jacobson","year":"2015","journal-title":"J\u00a0Exp Med"},{"key":"2023080716253521200_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The immunobiology of interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2023080716253521200_bib35","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.4049\/jimmunol.1600652","article-title":"IL-27 directly enhances germinal center B cell activity and potentiates lupus in sanroque mice","volume":"197","author":"Vijayan","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2023080716253521200_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1189\/jlb.1210660","article-title":"Interleukin-27 and interleukin-23 modulate human plasmacell functions","volume":"89","author":"Cocco","year":"2011","journal-title":"J\u00a0Leukoc Biol"},{"issue":"16","key":"2023080716253521200_bib37","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1158\/1078-0432.CCR-10-0173","article-title":"Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma","volume":"16","author":"Cocco","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2023080716253521200_bib38","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1074\/jbc.M005458200","article-title":"JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells","volume":"276","author":"Aurrand-Lions","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"49","key":"2023080716253521200_bib39","doi-asserted-by":"crossref","first-page":"45826","DOI":"10.1074\/jbc.M105972200","article-title":"Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor","volume":"276","author":"Arrate","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"2023080716253521200_bib40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1158\/0008-5472.CAN-12-1756","article-title":"Homing of human B cells to lymphoid organs and B-cell lymphoma engraftment are controlled by cell adhesion molecule JAM-C","volume":"73","author":"Donate","year":"2013","journal-title":"Cancer Res"},{"issue":"7","key":"2023080716253521200_bib41","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2001-11-0098","article-title":"Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration","volume":"100","author":"Johnson-Leger","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2023080716253521200_bib42","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \"many and multiple myelomas\" and of new targets for myeloma therapy","volume":"91","author":"Bataille","year":"2006","journal-title":"Haematologica"},{"issue":"12","key":"2023080716253521200_bib43","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.4049\/jimmunol.1103720","article-title":"In\u00a0vitro generation of long-lived human plasma cells","volume":"189","author":"Cocco","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2023080716253521200_bib44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.2100623","article-title":"APRIL drives a coordinated but diverse response as a foundation for plasma cell longevity","volume":"209","author":"Stephenson","year":"2022","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"2023080716253521200_bib45","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.4049\/jimmunol.177.12.8381","article-title":"Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells","volume":"177","author":"Konforte","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"2023080716253521200_bib46","doi-asserted-by":"crossref","first-page":"599648","DOI":"10.3389\/fimmu.2020.599648","article-title":"IL-21-deficient T follicular helper cells support B cell responses through IL-27 in patients with chronic hepatitis B","volume":"11","author":"Khanam","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2023080716253521200_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-kappaB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2023080716253521200_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/biomedicines5030050","article-title":"Unlocking the NF-kappaB conundrum: embracing complexity to achieve specificity","volume":"5","author":"Begalli","year":"2017","journal-title":"Biomedicines"},{"issue":"5","key":"2023080716253521200_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-13-0585","article-title":"A\u00a0small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity","volume":"4","author":"Shono","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"2023080716253521200_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccr.2014.07.027","article-title":"Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta\/MKK7 inhibitors","volume":"26","author":"Tornatore","year":"2014","journal-title":"Cancer Cell"},{"key":"2023080716253521200_bib51","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1038\/ncomms9428","article-title":"Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth","volume":"6","author":"Vallabhapurapu","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"2023080716253521200_bib52","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/bloodadvances.2021004354","article-title":"Junctional adhesion molecule C expression specifies a CD138low\/neg multiple myeloma cell population in mice and humans","volume":"6","author":"Brandl","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023080716253521200_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cei.13116","article-title":"IL-27: a double agent in the IL-6 family","volume":"193","author":"Jones","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2023080716253521200_bib54","doi-asserted-by":"crossref","first-page":"e66014","DOI":"10.7554\/eLife.66014","article-title":"Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses","volume":"10","author":"Wilmes","year":"2021","journal-title":"Elife"},{"issue":"9","key":"2023080716253521200_bib55","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.leukres.2013.06.022","article-title":"Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival","volume":"37","author":"Song","year":"2013","journal-title":"Leuk Res"},{"key":"2023080716253521200_bib56","doi-asserted-by":"crossref","first-page":"613007","DOI":"10.3389\/fimmu.2020.613007","article-title":"PD-L1\/PD-1 pattern of expression within the bone marrow immune microenvironment in smoldering myeloma and active multiple myeloma patients","volume":"11","author":"Costa","year":"2020","journal-title":"Front Immunol"},{"issue":"13","key":"2023080716253521200_bib57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10027","key":"2023080716253521200_bib58","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"2023080716253521200_bib59","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023080716253521200_bib60","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"2023080716253521200_bib61","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garcia-Guerrero","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2023080716253521200_bib62","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023080716253521200_bib63","doi-asserted-by":"crossref","first-page":"e98745","DOI":"10.1172\/jci.insight.98745","article-title":"IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy","volume":"3","author":"Zhu","year":"2018","journal-title":"JCI Insight"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3874\/2069868\/blooda_adv-2022-009044-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3874\/2069868\/blooda_adv-2022-009044-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:26:23Z","timestamp":1691425583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/3874\/494802\/Cytokine-receptor-IL27RA-is-an-NF-B-responsive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":63,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009044","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}